Cargando…
Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters
Chronic hepatitis C (HCV) infection perturbs lipid and glucose metabolism. The influence of direct acting antiviral (DAA) treatment and ribavirin on these measures was evaluated. Furthermore, the effect of HCV cure on these parameters was assessed. Participants were allocated to one of three 12-week...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468811/ https://www.ncbi.nlm.nih.gov/pubmed/30884773 http://dx.doi.org/10.3390/cells8030252 |
_version_ | 1783411519513427968 |
---|---|
author | Doyle, Mary-Anne Galanakis, Chrissi Mulvihill, Erin Crawley, Angela Cooper, Curtis L. |
author_facet | Doyle, Mary-Anne Galanakis, Chrissi Mulvihill, Erin Crawley, Angela Cooper, Curtis L. |
author_sort | Doyle, Mary-Anne |
collection | PubMed |
description | Chronic hepatitis C (HCV) infection perturbs lipid and glucose metabolism. The influence of direct acting antiviral (DAA) treatment and ribavirin on these measures was evaluated. Furthermore, the effect of HCV cure on these parameters was assessed. Participants were allocated to one of three 12-week treatment groups: non-cirrhotic genotype 1a-paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD) plus ribavirin; non-cirrhotic 1b-PrOD; compensated cirrhotic 1a or 1b-PrOD plus ribavirin. Fasting insulin, glucose, lipid and apolipoprotein measures were assessed at baseline, Treatment Weeks 4 and 12, and 12 and 24 weeks post-dosing. Twenty-three of 24 participants achieved SVR (PP= 23/24, 96% SVR). Overall, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels all increased in treatment and post-dosing. However, LDL-C levels decreased during treatment in ribavirin recipients. Fasting glucose, insulin, and HOMA-IR were unchanged during treatment and 12 weeks post-treatment. By 12 weeks post-treatment, controlled attenuation parameter (CAP) scores, a measure of steatosis, increased from baseline (mean 30.3 ± 63.5, p = 0.05). This regimen was safe and highly effective and did not influence glucose metabolism. Ribavirin exposure may mitigate some on-treatment lipid changes. Further mechanistic studies are needed to understand how ribavirin impacts lipid pathways, as there could be therapeutic implications. The metabolic pathophysiology of increased CAP score with HCV treatment requires explanation. |
format | Online Article Text |
id | pubmed-6468811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64688112019-04-23 Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters Doyle, Mary-Anne Galanakis, Chrissi Mulvihill, Erin Crawley, Angela Cooper, Curtis L. Cells Article Chronic hepatitis C (HCV) infection perturbs lipid and glucose metabolism. The influence of direct acting antiviral (DAA) treatment and ribavirin on these measures was evaluated. Furthermore, the effect of HCV cure on these parameters was assessed. Participants were allocated to one of three 12-week treatment groups: non-cirrhotic genotype 1a-paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD) plus ribavirin; non-cirrhotic 1b-PrOD; compensated cirrhotic 1a or 1b-PrOD plus ribavirin. Fasting insulin, glucose, lipid and apolipoprotein measures were assessed at baseline, Treatment Weeks 4 and 12, and 12 and 24 weeks post-dosing. Twenty-three of 24 participants achieved SVR (PP= 23/24, 96% SVR). Overall, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels all increased in treatment and post-dosing. However, LDL-C levels decreased during treatment in ribavirin recipients. Fasting glucose, insulin, and HOMA-IR were unchanged during treatment and 12 weeks post-treatment. By 12 weeks post-treatment, controlled attenuation parameter (CAP) scores, a measure of steatosis, increased from baseline (mean 30.3 ± 63.5, p = 0.05). This regimen was safe and highly effective and did not influence glucose metabolism. Ribavirin exposure may mitigate some on-treatment lipid changes. Further mechanistic studies are needed to understand how ribavirin impacts lipid pathways, as there could be therapeutic implications. The metabolic pathophysiology of increased CAP score with HCV treatment requires explanation. MDPI 2019-03-15 /pmc/articles/PMC6468811/ /pubmed/30884773 http://dx.doi.org/10.3390/cells8030252 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Doyle, Mary-Anne Galanakis, Chrissi Mulvihill, Erin Crawley, Angela Cooper, Curtis L. Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters |
title | Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters |
title_full | Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters |
title_fullStr | Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters |
title_full_unstemmed | Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters |
title_short | Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters |
title_sort | hepatitis c direct acting antivirals and ribavirin modify lipid but not glucose parameters |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468811/ https://www.ncbi.nlm.nih.gov/pubmed/30884773 http://dx.doi.org/10.3390/cells8030252 |
work_keys_str_mv | AT doylemaryanne hepatitiscdirectactingantiviralsandribavirinmodifylipidbutnotglucoseparameters AT galanakischrissi hepatitiscdirectactingantiviralsandribavirinmodifylipidbutnotglucoseparameters AT mulvihillerin hepatitiscdirectactingantiviralsandribavirinmodifylipidbutnotglucoseparameters AT crawleyangela hepatitiscdirectactingantiviralsandribavirinmodifylipidbutnotglucoseparameters AT coopercurtisl hepatitiscdirectactingantiviralsandribavirinmodifylipidbutnotglucoseparameters |